Meningitis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Meningitis – Pipeline Review, H1 2020’, provides an overview of the Meningitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Meningitis

– The report reviews pipeline therapeutics for Meningitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Meningitis therapeutics and enlists all their major and minor projects

– The report assesses Meningitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Meningitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Meningitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Meningitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CanSino Biologics Inc

Chongqing Zhifei Biological Products Co Ltd

Eubiologics Co Ltd

FUJIFILM Toyama Chemical Co Ltd

Liaoning Cheng Da Biotechnology Co Ltd

Linnaeus Bioscience Inc

Matinas BioPharma Holdings Inc

Mycovia Pharmaceuticals Inc

Olymvax Biopharmaceuticals Inc

Pneumagen Ltd

TGV Therapeutics

Yisheng Biopharma Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Meningitis - Overview

Meningitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Meningitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Meningitis - Companies Involved in Therapeutics Development

CanSino Biologics Inc

Chongqing Zhifei Biological Products Co Ltd

Eubiologics Co Ltd

FUJIFILM Toyama Chemical Co Ltd

Liaoning Cheng Da Biotechnology Co Ltd

Linnaeus Bioscience Inc

Matinas BioPharma Holdings Inc

Mycovia Pharmaceuticals Inc

Olymvax Biopharmaceuticals Inc

Pneumagen Ltd

TGV Therapeutics

Yisheng Biopharma Co Ltd

Meningitis - Drug Profiles

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae type b + rotavirus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSB-015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EUC-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flucytosine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A and C] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MYC-053 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neumifil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal [serotype 4, 6A] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Cryptococcal Meningitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GWT1 for Cryptococcal Meningitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-2307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1129 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1598 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Meningitis - Dormant Projects

Meningitis - Discontinued Products

Meningitis - Product Development Milestones

Featured News & Press Releases

Feb 19, 2020: Matinas BioPharma announces DSMB approval to commence part 2 of EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of Cryptococcal Meningitis

Oct 14, 2019: Matinas BioPharma initiates EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of fungal cryptococcal meningitis

Oct 07, 2019: Matinas BioPharma receives orphan drug designation from U.S. FDA for MAT2203 for the treatment of cryptococcosis

Jul 25, 2019: Matinas BioPharma receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis

Jun 03, 2019: Matinas BioPharma to present on MAT2203 at the 9th Annual LD Micro Invitational

May 28, 2019: Matinas BioPharma announces publication of MAT2203 Preclinical Cryptococcal Meningitis data in the American Society for Microbiology Journal, mBio

May 01, 2019: Matinas BioPharma selected to present at the BioNJ Ninth Annual BioPartnering Conference

Dec 20, 2018: Matinas BioPharma to present data on MAT2203 at Biotech Showcase 2019

Aug 08, 2017: Matinas BioPharma Reaffirms Clinical and Regulatory Strategy to Advance MAT2203

Jun 02, 2017: Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis

May 30, 2017: Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology's ASM Microbe 2017 Conference

Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated

Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis

Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis

Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Meningitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Meningitis – Pipeline by CanSino Biologics Inc, H1 2020

Meningitis – Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020

Meningitis – Pipeline by Eubiologics Co Ltd, H1 2020

Meningitis – Pipeline by FUJIFILM Toyama Chemical Co Ltd, H1 2020

Meningitis – Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, H1 2020

Meningitis – Pipeline by Linnaeus Bioscience Inc, H1 2020

Meningitis – Pipeline by Matinas BioPharma Holdings Inc, H1 2020

Meningitis – Pipeline by Mycovia Pharmaceuticals Inc, H1 2020

Meningitis – Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020

Meningitis – Pipeline by Pneumagen Ltd, H1 2020

Meningitis – Pipeline by TGV Therapeutics, H1 2020

Meningitis – Pipeline by Yisheng Biopharma Co Ltd, H1 2020

Meningitis – Dormant Projects, H1 2020

Meningitis – Dormant Projects, H1 2020 (Contd..1), H1 2020

Meningitis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Meningitis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports